ASCO GI Conference Coverage

Ipsen to Present Data at ASCO GI 2018, Including New Post-Hoc Analyses from ONIVYDE® (irinotecan liposome injection) Phase 3 NAPOLI-1 Trial

(Yahoo! Finance) Jan 17, 2018 - Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, today announced that five new sub-analyses of the pivotal Phase 3 NAPOLI-1 trial will be presented at this year’s American Society of Clinical Oncology’s Gastrointestinal Cancer Symposium (ASCO GI) taking place in San Francisco, California, from January 18-20.

read article

Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers Symposium

(Morningstar) Jan 18, 2018 - MacroGenics, Inc. today announced presentation of data from its clinical trial of margetuximab plus pembrolizumab for patients with advanced gastric and gastroesophageal junction (GEJ) cancers in a poster session at the 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, California.

read article

First-Time Data for Merck’s KEYTRUDA® (pembrolizumab) in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) to be Presented at 2018 ASCO GI Symposium

(Merck) Jan 19, 2018 - Merck, known as MSD outside the United States and Canada, today announced findings from the registrational phase 2 KEYNOTE-224 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with advanced hepatocellular carcinoma (HCC), the most common type of liver cancer, who were previously treated with systemic therapy (sorafenib).

read corporate press release

Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium

(Business Insider) Jan 18, 2018 - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that updated phase 1 safety and efficacy data for DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), in a subgroup of patients with HER2-expressing gastric cancer previously treated with trastuzumab and chemotherapy were presented during a poster session at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco, California.

read article

Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma

(Morningstar) Jan 16, 2018 - Exelixis, Inc. and Ipsen today announced detailed results of the pivotal phase 3 CELESTIAL trial in patients with previously treated advanced hepatocellular carcinoma (HCC), which will be presented in a late-breaking oral session at the 2018 ASCO-GI Symposium being held in San Francisco, January 18-20, 2018.

read article

TGen-HonorHealth Research Institute Clinical Trial Reports High Rate of Tumor Shrinkage Among Patients with Advanced Pancreatic Cancer

(TGen) Apr 25, 2017 - Adding cisplatin to the standard gemcitabine/nab-paclitaxel drug treatment provided a very high rate of tumor shrinkage for patients with advanced pancreatic cancer, according to the results of a pilot clinical trial conducted by the HonorHealth Research Institute and the Translational Genomics Research Institute (TGen).

read press release

Liquid Biopsy Test Shows Promise for Detecting Early-Stage Colorectal Cancer

(ASCO) Jan 16, 2018 - A new study has found that a test that identifies circulating tumor cells (CTCs) present in the bloodstream can detect colorectal cancer at an early stage, with accuracy ranging from 84 to 88%.

read press release

Liquid Biopsy Shows Promise for Colon Cancer

(MedPage Today) Jan 16, 2018 - A liquid biopsy detected circulating tumor cells (CTCs) associated with colorectal cancer with overall accuracy approaching 90%, according to a study reported here.

read article (free registration required)

Taiho Oncology and Servier Present LONSURF® (trifluridine and tipiracil) Metastatic Colorectal Cancer (mCRC) Data at ASCO 2018 Gastrointestinal Cancers Symposium

(Business Insider) Jan 20, 2018 - Taiho Oncology, Inc. and Servier today announced clinical data for LONSURF® (trifluridine and tipiracil) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild type, an anti-EGFR therapy.

read article

Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

(Exelixis) Jan 20, 2018 - Exelixis, Inc. today announced the presentation of updated results from the Genentech-sponsored phase 1b clinical trial of cobimetinib (COTELLIC®), an Exelixis-discovered MEK inhibitor, in combination with atezolizumab (TECENTRIQ®), an anti-PDL1 antibody discovered and developed by Genentech, a member of the Roche Group, in patients with metastatic colorectal cancer (CRC).

read corporate press release

Therapy Order Affects Survival in Metastatic CRC

(MedPage Today) Jan 21, 2018 - A strategy that had minimal impact on chemotherapy success made a significant difference in targeted therapies' impact on colorectal cancer survival, according to a small randomized study.

read article (free registration required)

Question Over Ramucirumab in First-Line Gastric Cancer

(Medscape Medical News) Jan 19, 2018 - Adding the antiangiogenesis agent ramucirumab (Cyramza, Eli Lilly) to first-line chemotherapy conferred a significant reduction in the risk for disease progression or death among patients with metastatic gastric or gastroesophageal junction adenocarcinoma, according to results of the RAINFALL trial.

read article (free registration required)

Immunotherapy Combo Active in High-Risk CRC

(MedPage Today) Jan 22, 2018 - More than half of patients with previously treated metastatic colorectal cancer and DNA mismatch repair deficiency (dMMR) had objective responses to the immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy), results of a cohort study showed.

read article (free registration required)

Combo Tx Active in Locally Advanced Pancreatic Ca

(MedPage Today) Jan 21, 2018 - Time to treatment failure in newly diagnosed locally advanced pancreatic cancer exceeded historical standards in patients who received induction therapy with nab-paclitaxel (Abraxane) and gemcitabine, a preliminary trial showed.

read article (free registration required)

Eisai Presents Results Of Analysis Of Phase III Trial Of Lenvima® (Lenvatinib) in Hepatocellular Carcinoma Based On Independent Imaging Review At ASCO-GI

(Eisai) Jan 22, 2018 - Eisai Co., Ltd. announced today that the results of an analysis of a Phase III trial (REFLECT study / Study 304)1 of its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima® / Kisplyx®, “lenvatinib”) versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma based on independent imaging review were presented2 during the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) 2018, in San Francisco, the United States.

read corporate press release

AVEO Oncology Announces Presentation of Data from Phase 1b/2 Study of Tivozanib in Patients with Advanced Hepatocellular Carcinoma

(AVEO Oncology) Jan 19, 2018 - AVEO Oncology today announced the presentation of data from a multicenter, Phase 1b/2 study of FOTIVDA® (tivozanib), a potent, elective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors, in patients with advanced, unresectable hepatocellular carcinoma (HCC).

read corporate press release

Investigational Data Presented at ASCO GI Evaluate ABRAXANE® Regimen for Patients with Locally Advanced Pancreatic Cancer

(Yahoo! Finance) Jan 20, 2018 - Celgene Corporation today announced primary endpoint findings and updated results of secondary endpoints from the phase II international LAPACT trial of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) plus gemcitabine in patients with locally advanced pancreatic cancer.

read article

Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial

(Morningstar) Jan 20, 2018 - Array BioPharma Inc. and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF-mutant metastatic colorectal cancer (CRC) whose disease has progressed after one or two prior regimens.

read article

Nivolumab's Durable Responses in MMR/MSI Colorectal Cancer

(Medscape Medical News) Jan 26, 2018 - There are now more data to support the use of nivolumab (Opdivo, Bristol-Meyers Squibb) as a treatment for DNA mismatch repair-deficient (dMMR)/microsatellite instability–high (MSI-H) metastatic colorectal cancer (mCRC), either as a monotherapy or in combination.

read article (free registration required)